

Statement of Financial Results for the quarter ended 30th June 2020

Particulars	Quarter ended			Year ended
	30-Jun-20	31-Mar-20	30-Jun-19	31-Mar-20
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1 Revenue from Operations	9,165	8,867	9,404	37,557
2 Other Income	45	38	16	73
3 Total Income	9,210	8,905	9,420	37,630
4 Expenses				
(a) Cost of Materials Consumed	1,914	1,817	1,677	7,513
(b) Purchases of Stock-in-Trade	1,505	927	1,134	5,861
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(492)	308	462	(598)
(d) Employee Benefits Expense	2,400	2,368	2,312	9,590
(e) Finance Costs	31	30	73	175
(f) Depreciation and Amortisation Expense	416	412	392	1,636
(g) Other Expenses	2,153	2,197	2,284	9,276
Total Expenses	7,927	8,059	8,334	33,453
5 Profit before exceptional items and tax	1,283	846	1,086	4,177
6 Exceptional Items Gain/(Loss) (See Note 4)	-	(532)	-	(532)
7 Profit before tax	1,283	314	1,086	3,645
8 Income tax expenses				
a. Current Tax	411	62	300	1,010
b. Deferred Tax	(34)	(46)	(49)	(266)
9 Profit for the period	906	298	835	2,901
10 Other Comprehensive Income				
(i) Items that will not be reclassified to Profit or Loss	(6)	6	(10)	(24)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	(1)	3	7
Other Comprehensive Income Net of Tax	(4)	5	(7)	(17)
11 Total Comprehensive Income for the period	902	303	828	2,884
12 Paid-up Equity Share Capital (Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323
13 Other Equity				16,334
14 Total Earning per Share from operations (of Rs. 8/- each) (not annualised):				
(a) Basic	5.48	1.80	5.05	17.54
(b) Diluted	5.48	1.80	5.05	17.54

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 31, 2020.
- Figures for the quarter ended March 31, 2020 are the balancing figures between the audited financial results for the year ended March 31, 2020 and the published unaudited financial results for the nine months ended December 31, 2019 which were subjected to a limited review.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- Exceptional items for the year ended March 31, 2020 relates to write off of an intangible asset under development. The Company does not expect any future economic benefits to flow to the Company hence the cost incurred till date have been charged off during the quarter ended March 31, 2020.
- In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. As indicated in the notes to the results for the quarter ended March 31, 2020, the Company continues to monitor the situation and has adopted stringent measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption.
The Company has considered internal and external information while finalizing various estimates in relation to its financial results upto the date of approval of the financial results by the Board of Directors. The actual impact of the global health pandemic may be different from that which has been estimated, as the COVID -19 situation evolves in India and globally. The Company continues to track any material changes to expected future economic conditions.

For RPG Life Sciences Limited

Yugal Sikri
Managing Director
Mumbai, July 31, 2020